Login
$TXG
$54.51 -$0.48 (0.87%) After hours

$TXG 8-K SEC Filings

Filed On Filing
05 Nov 2026 8-K: Results of Operations and Financial Condition

PLEASANTON, Calif. November 5, 2026 – 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today reported financial results for the third quarter ended September...

02 Nov 2026 8-K: Departure/Election of Directors or Officers; Compensation

On October 28, 2026, upon the recommendation of its Nominating and Corporate Governance Committee, the Board of Directors of 10x Genomics, Inc. (the “Company”) appointed Ansuman Satpathy and Joseph Gilliam to the Board of Directors as Cl...

06 Aug 2026 8-K: Results of Operations and Financial Condition

PLEASANTON, Calif. August 6, 2026 – 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today reported financial results for the second quarter ended June 30, 2...

08 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders

The annual meeting of stockholders of 10x Genomics, Inc. (the "Company") was held on June 4, 2026 via live webcast (the “Annual Meeting”). At the Annual Meeting, there were present, virtually or by proxy, holders of 117,542,161 shares of...

07 May 2026 8-K: Results of Operations and Financial Condition

PLEASANTON, Calif. May 7, 2026 – 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the first quarter ended March 31, 2026.

12 Feb 2026 8-K: Results of Operations and Financial Condition

PLEASANTON, Calif. February 12, 2026 – 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the fourth quarter and full year ended December 31, 2025 and provided its outlook ...

12 Jan 2026 8-K: Results of Operations and Financial Condition

PLEASANTON, Calif., January 11, 2026 — 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced preliminary, unaudited select results for the fourth quarter and full year ended December 31, 2025.

14 Nov 2025 8-K: Departure/Election of Directors or Officers; Compensation

After more than eight years of exemplary service, on November 12, 2025 Eric S. Whitaker announced his intention to retire as Chief Legal Officer of 10x Genomics, Inc. (the “Company”) effective January 1, 2026. Mr. Whitaker will remain an...

06 Nov 2025 8-K: Results of Operations and Financial Condition

PLEASANTON, Calif. November 6, 2025 – 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the third quarter ended September 30, 2025.

07 Aug 2025 8-K: Results of Operations and Financial Condition

PLEASANTON, Calif. August 7, 2025 – 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the second quarter ended June 30, 2025.

05 Jun 2025 8-K: Submission of Matters to a Vote of Security Holders

The annual meeting of stockholders of 10x Genomics, Inc. (the "Company") was held on June 3, 2025 via live webcast (the “Annual Meeting”). At the Annual Meeting, there were present, virtually or by proxy, holders of 108,937,350 shares of...

14 May 2025 8-K: Other Events

On May 12, 2025, 10x Genomics, Inc. (the “Company”) entered into a settlement agreement and license agreements (the “Agreements”) with Bruker Corporation (“Bruker”) resolving all outstanding litigation and other proceedings between the p...

08 May 2025 8-K: Results of Operations and Financial Condition; Costs Associated with Exit or Disposal Activities

PLEASANTON, Calif. May 8, 2025 – 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the first quarter ended March 31, 2025.

12 Feb 2025 8-K: Results of Operations and Financial Condition

PLEASANTON, Calif. February 12, 2025 – 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the fourth quarter and full year ended December 31, 2024 and provided outlook for ...

13 Jan 2025 8-K: Results of Operations and Financial Condition

FY 2024 revenue of ~$611 million and Q4 2024 revenue of ~$165 million, representing 9% growth sequentially

29 Oct 2024 8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation

PLEASANTON, Calif. October 29, 2024 – 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the third quarter ended September 30, 2024.

09 Oct 2024 8-K: Results of Operations and Financial Condition

PLEASANTON, Calif., October 9, 2024 – 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced preliminary select results for the third quarter ended September 30, 2024.

08 Aug 2024 8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation +1 more

PLEASANTON, Calif. August 8, 2024 – 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the second quarter ended June 30, 2024.

11 Jul 2024 8-K: Departure/Election of Directors or Officers; Compensation

On July 10, 2024, upon the recommendation of its Nominating and Corporate Governance Committee, the Board of Directors of 10x Genomics, Inc. (the “Company”) appointed Sarah A. Teichmann to the Board of Directors as a Class II director ef...

20 Jun 2024 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support